Pharmacologic Activation of the Innate Immune System to Prevent Respiratory Viral Infections
- 1 September 2011
- journal article
- Published by American Thoracic Society in American Journal of Respiratory Cell and Molecular Biology
- Vol. 45 (3), 480-488
- https://doi.org/10.1165/rcmb.2010-0288oc
Abstract
Drugs that can rapidly inhibit respiratory infection from influenza or other respiratory pathogens are needed. One approach is to engage primary innate immune defenses against viral infection, such as activating the IFN pathway. In this study, we report that a small, cell-permeable compound called 5,6-di-methylxanthenone-4-acetic acid (DMXAA) can induce protection against vesicular stomatitis virus in vitro and H1N1 influenza A virus in vitro and in vivo through innate immune activation. Using the mouse C10 bronchial epithelial cell line and primary cultures of nasal epithelial cells, we demonstrate DMXAA activates the IFN regulatory factor-3 pathway leading to production of IFN-β and subsequent high-level induction of IFN-β-dependent proteins, such as myxovirus resistance 1 (Mx1) and 2',5'-oligoadenylate synthetase 1 (OAS1). Mice treated with DMXAA intranasally elevate mRNA/protein expression of Mx1 and OAS1 in the nasal mucosa, trachea, and lung. When challenged intranasally with a lethal dose of H1N1 influenza A virus, DMXAA reduced viral titers in the lungs and protected 80% of mice from death, even when given at 24 hours before infection. These data show that agents, like DMXAA, that can directly activate innate immune pathways, such as the IFN regulatory factor-3/IFN-β system, in respiratory epithelial cells can be used to protect from influenza pneumonia and potentially in other respiratory viral infections. Development of this approach in humans could be valuable for protecting health care professionals and "first responders" in the early stages of viral pandemics or bioterror attacks.Keywords
This publication has 46 references indexed in Scilit:
- Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulationBiochemical Pharmacology, 2011
- Activation of the Nucleotide Oligomerization Domain Signaling Pathway by the Non-bacterially Derived Xanthone Drug 5′6-Dimethylxanthenone-4-acetic Acid (Vadimezan)*Online Journal of Public Health Informatics, 2010
- Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-β for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential EfficacyHuman Gene Therapy, 2010
- Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivoMucosal Immunology, 2009
- Rotavirus and Reovirus Modulation of the Interferon ResponseJournal of Interferon & Cytokine Research, 2009
- Activation of innate immune antiviral responses by Nod2Nature Immunology, 2009
- Type I IFNs mediate development of postinfluenza bacterial pneumonia in miceJCI Insight, 2009
- Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10Nature Medicine, 2009
- Type I IFN innate immune response to adenovirus-mediated IFN-γ gene transfer contributes to the regression of cutaneous lymphomasJCI Insight, 2007
- The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axisThe Journal of Experimental Medicine, 2007